Organic Active Ingredients TRIZ Cases

Ex vivo human intestinal enteroids combined with bile components enable robust replication of mammalian viruses in controlled culture environments.

Liquid fumarate ester suspension in a lipid matrix within soft gelatin capsules prevents enteric coating cracking and sublimation losses.

CNNM4 inhibitors target biological markers to treat fibrotic conditions.

Alkyne coupling reaction produces tricyclic compounds using copper and palladium catalysts, resolving synthesis step complexity.

An alcohol and glycol cosolvent mixture dissolves buprenorphine and naloxone in a sublingual spray, resolving storage stability issues at elevated temperatures.

Combines kinase inhibitors with androgen receptor antagonists to restore drug sensitivity in resistant prostate cancer.

Liposomal mitoxantrone and pegaspargase treat NK T-cell lymphoma while reducing systemic toxicity.

Site-specific conjugation via engineered cysteines creates homogeneous ADCs that reduce non-specific toxicity while maintaining high affinity.

A compound acting as an estrogen receptor alpha-inhibiting beta partial agonist provides targeted therapeutic action.

siRNA molecules silence the FLAP gene to reduce allergic inflammation, addressing short drug duration and side effects.

Isocitrate modulates aconitase activity to overcome erythroid repression, improving erythropoietin efficacy while preventing iron overload risks.

Oxazole compounds activate IDO1 and AhR pathways to reduce anti-inflammatory cytokines and enhance immune cell activity.

Synthetic aptamers bind autoantibodies targeting the beta-1-adrenergic receptor extracellular loop.

Triflimide catalyzed reaction of Compound 2 with paraldehyde increases obeticholic acid yield and purity while reducing production costs.

Optimizing crystalline polymorphs improves stability and purity, addressing manufacturing complexity in Kennedy's disease treatments.

Lipophilic coating on inert cores controls venlafaxine hydrochloride release kinetics, resolving rapid dissolution and frequent dosing requirements.

Trimeprazine dosing maintains treatment effectiveness over time, resolving the trade-off between efficacy and compliance.

Preorienting elongate drug crystals at specific angles prevents separation from the balloon surface during insertion, ensuring effective therapeutic delivery.

Enteric-coated solid oral irinotecan formulations with non-ionic surfactants address low bioavailability by ensuring consistent intestinal absorption.

Nalmefene reduces inflammatory hepatic injury by inhibiting TNF-alpha release and p38 MAP kinase phosphorylation in Kupffer cells.

Measuring FLIP, Sp1, and Sp3 biomarkers distinguishes aggressive from indolent tumors to reduce unnecessary treatments.

Replacing castor oil with dimethyl sulfoxide and triglycerides reduces injection pain while maintaining long-term stability.

Low-dose domperidone accelerates antibody titre reduction while minimizing adverse effects.

A proanthocyanidin pharmaceutical composition promotes damaged liver regeneration and improves hepatic function in patients with liver disease.

A mouth rinse formulation combines vanilla flavor extract with menthol derivatives to mask the bitter taste of C2-C5 diacid salts.

Quantifies clotting biomarkers like Factor VIII to predict relapse risk, enabling timely steroid intervention before symptom onset.

Liquid lipid nanoparticle emulsion solubilizes water-insoluble ticagrelor in aqueous media.

Inhibiting the pro-inflammatory MRP2/HXA3 pathway while enhancing anti-inflammatory P-gp activity resolves excessive neutrophil migration and tissue damage.

A modified release amino acid formulation mimics natural protein digestion kinetics to stabilize metabolic markers.

Targeting Factor D suppresses complement amplification, addressing inadequate coverage of dry and neovascular AMD mechanisms.

Ovatodiolide targets cysteine proteases to inhibit viral replication, reducing adverse effects and drug resistance associated with current antiviral therapies.

A transdermal therapeutic system uses a fibrous solid phase to release water-soluble peptides through an occlusive backing layer.

Depolymerized HE800 exopolysaccharides reduce cancer cell viability without inducing bleeding complications associated with heparin.

Sodium bicarbonate infusion corrects metabolic acidosis to accelerate postoperative awakening, reducing ICU care duration and anesthesiologist workload.

Combining entinostat with anti-PD-1 antibodies modulates immune responses to treat cancer.

Boronic acid compounds overcome drug resistance and reduce toxic side effects through multi-target molecular architecture.

Deuterium substitution extends the in vivo half-life of obeticholic acid derivatives, reducing dosage requirements despite increased synthesis complexity.

HPMCAS powder with controlled particle size dissolves rapidly in solvents, preventing filter and nozzle clogging during enteric coating processes.

Water-soluble N-vinylpyrrolidone and acrylic acid copolymers form solid solutions with basic active ingredients to enhance drug solubility.

A nucleic acid composition links single-stranded DNA to double-stranded RNA for targeted endosomal delivery.

NANOG antagonists block homeodomain protein function to prevent tumor recurrence and reduce growth.

Antisense oligonucleotides bypass AAV cargo size limits by excluding aberrant CEP290 exons, restoring normal splicing and protein production.

CTRP6 agonists stimulate PAQR1 and PAQR4 receptors to promote chondrocyte proliferation, addressing the lack of effective treatments for cartilage degeneration.

Formula I compounds inhibit Mnk kinase activity to attenuate tumor growth and overcome limited clinical utility of existing inhibitors.